{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:45:31Z","timestamp":1774673131901,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lfs.2022.121176","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T03:48:55Z","timestamp":1668052135000},"page":"121176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"PA","title":["Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice"],"prefix":"10.1016","volume":"311","author":[{"given":"Mi-Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendalyn","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121176_bb0005","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2022.121176_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.770986","article-title":"Endotoxins and non-alcoholic fatty liver disease","volume":"12","author":"Kessoku","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2022.121176_bb0015","doi-asserted-by":"crossref","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","article-title":"Hepatic TLR4 signaling in obese NAFLD","volume":"309","author":"Sharifnia","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.lfs.2022.121176_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000163037","article-title":"Role of intestinal mucins in innate host defense mechanisms against pathogens","volume":"1","author":"Dharmani","year":"2009","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.lfs.2022.121176_bb0025","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2022.121176_bb0030","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3389\/fimmu.2020.02054","article-title":"Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies","volume":"11","author":"Grondin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2022.121176_bb0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-230X-12-156","article-title":"Lubiprostone stimulates small intestinal mucin release","volume":"12","author":"De Lisle","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.lfs.2022.121176_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/CIA.S2938","article-title":"Lubiprostone: a novel treatment for chronic constipation","volume":"3","author":"Lacy","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.lfs.2022.121176_bb0045","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.dld.2022.04.012","article-title":"Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis","volume":"54","author":"Enomoto","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.lfs.2022.121176_bb0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000503054","article-title":"Lubiprostone induces Claudin-1 and protects intestinal barrier function","volume":"105","author":"Nishii","year":"2020","journal-title":"Pharmacology"},{"key":"10.1016\/j.lfs.2022.121176_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175626","article-title":"Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: a prospective randomized pilot study in healthy volunteers","volume":"12","author":"Kato","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2022.121176_bb0060","first-page":"996","article-title":"Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial, lancet","volume":"5","author":"Kessoku","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2022.121176_bb0065","doi-asserted-by":"crossref","first-page":"21240","DOI":"10.3390\/ijms141121240","article-title":"Lessons from mouse models of high-fat diet-induced NAFLD","volume":"14","author":"Nakamura","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2022.121176_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218096","article-title":"Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice","volume":"14","author":"Arakawa","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2022.121176_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2022.121176_bb0080","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1074\/jbc.M117.796631","article-title":"Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent toll-like receptor 4 internalization and LPS-induced TBK1-IKK\u03f5-IRF3 axis activation","volume":"293","author":"Tsukamoto","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2022.121176_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6729","article-title":"Enterically derived high-density lipoprotein restrains liver injury through the portal vein","volume":"373","author":"Han","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.lfs.2022.121176_bb0090","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.lfs.2022.121176_bb0095","first-page":"222","article-title":"Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability, cell Mol","volume":"1","author":"Luther","year":"2015","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2022.121176_bb0100","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver X receptors in lipid signalling and membrane homeostasis","volume":"14","author":"Wang","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.lfs.2022.121176_bb0105","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1172\/JCI75436","article-title":"Pediatric crohn disease patients exhibit specific ileal transcriptome and microbiome signature","volume":"124","author":"Haberman","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2022.121176_bb0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/jpet.114.213991","article-title":"Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors","volume":"349","author":"Hayashi","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2022.121176_bb0115","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1681\/ASN.2014060530","article-title":"Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD","volume":"26","author":"Mishima","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lfs.2022.121176_bb0120","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.14309\/00000434-200509001-00905","article-title":"Effects of Lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats: 905","volume":"100","author":"Crawford","year":"2005","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"10.1016\/j.lfs.2022.121176_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00498254.2015.1078522","article-title":"Involvement of oxidative stress and mitochondrial\/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes","volume":"46","author":"Eftekhari","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.lfs.2022.121176_bb0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2008-2231-21-28","article-title":"Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-\u03b1 cytokine genetic polymorphism","volume":"21","author":"Mandegary","year":"2013","journal-title":"Daru"},{"key":"10.1016\/j.lfs.2022.121176_bb0135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2893.2008.00971.x","article-title":"Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats","volume":"15","author":"Tsai","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.lfs.2022.121176_bb0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2022.121176_bb0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.121176_bb0150","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.121176_bb0155","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2022.121176_bb0160","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:05:13Z","timestamp":1758402313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522008761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":32,"alternative-id":["S0024320522008761"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121176","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121176"}}